NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, Price Target & More

$33.25 +0.27 (+0.82 %)
(As of 04/22/2018 06:44 AM ET)
Previous Close$33.25
Today's Range$32.49 - $33.30
52-Week Range$30.10 - $67.10
Volume857,332 shs
Average Volume757,062 shs
Market Capitalization$2.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.49

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers. It is also developing PRT2761, which is in Phase 2 for allergic conjunctivitis; and PCSK9 inhibitor in pre-clinical study for hypercholesterolemia. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTLA
CUSIPN/A
Phone650-246-7000

Debt

Debt-to-Equity Ratio0.30%
Current Ratio5.94%
Quick Ratio5.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.55 million
Price / Sales97.05
Cash FlowN/A
Price / CashN/A
Book Value$5.36 per share
Price / Book6.20

Profitability

EPS (Most Recent Fiscal Year)($4.81)
Net Income$-286,090,000.00
Net Margins-1,268.34%
Return on Equity-108.43%
Return on Assets-61.83%

Miscellaneous

Employees252
Outstanding Shares65,820,000

How to Become a New Pot Stock Millionaire

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals (NASDAQ:PTLA) announced its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating analysts' consensus estimates of ($1.46) by $0.05. The biopharmaceutical company earned $9.80 million during the quarter, compared to analysts' expectations of $3.71 million. Portola Pharmaceuticals had a negative net margin of 1,268.34% and a negative return on equity of 108.43%. Portola Pharmaceuticals's quarterly revenue was down 28.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.95) earnings per share. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

7 Wall Street analysts have issued twelve-month price targets for Portola Pharmaceuticals' stock. Their predictions range from $49.00 to $75.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $66.6667 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Mr. William Lis, CEO, Pres & Director (Age 54)
  • Ms. Mardi C. Dier, CFO & Exec. VP (Age 54)
  • Dr. John T. Curnutte, Exec. VP of R&D (Age 66)
  • Mr. Tao Fu, Chief Commercial & Bus. Officer & Exec. VP (Age 46)
  • Mr. John B. Moriarty Jr., Exec. VP & Gen. Counsel (Age 50)

Has Portola Pharmaceuticals been receiving favorable news coverage?

News articles about PTLA stock have been trending positive recently, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.44 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.71 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $33.25.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $2.19 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (PTLA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  293 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Portola Pharmaceuticals (NASDAQ:PTLA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Portola Pharmaceuticals in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 100.50%. The high price target for PTLA is $75.00 and the low price target for PTLA is $49.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.863.002.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.6667$66.6667$75.00$67.6667
Price Target Upside: 100.50% upside100.62% upside42.53% upside25.73% upside

Portola Pharmaceuticals (NASDAQ:PTLA) Consensus Price Target History

Price Target History for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018OppenheimerReiterated RatingBuyLowView Rating Details
3/13/2018William BlairReiterated RatingBuyMediumView Rating Details
3/13/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$53.00 -> $49.00HighView Rating Details
3/1/2018Morgan StanleyDowngradeOverweight -> Equal Weight$65.00HighView Rating Details
12/28/2017CitigroupReiterated RatingBuy$74.00LowView Rating Details
12/1/2017Goldman SachsInitiated CoverageBuy -> Buy$75.00HighView Rating Details
6/26/2017CowenBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings History and Estimates Chart

Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) Earnings Estimates

2018 EPS Consensus Estimate: ($4.80)
2019 EPS Consensus Estimate: ($0.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.53)($1.49)($1.51)
Q2 20182($1.43)($0.26)($0.85)
Q3 20182($1.38)($1.23)($1.31)
Q4 20182($1.26)($1.01)($1.14)
Q1 20191($0.56)($0.56)($0.56)
Q2 20191($0.30)($0.30)($0.30)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191$0.28$0.28$0.28

Portola Pharmaceuticals (NASDAQ PTLA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($1.22)N/AView Earnings Details
2/28/2018Q4 2017($1.46)($1.41)$3.71 million$9.80 millionViewListenView Earnings Details
11/6/2017Q3 2017($1.49)($1.41)$4.71 million$3.83 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.10)($1.22)$4.28 million$3.79 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
11/9/2015Q3 2015($1.24)($1.05)$2.40 million$2.91 millionViewN/AView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.4150 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
11/5/2013Q3 2013($0.68)($0.53)$2.00 million$2.77 millionViewN/AView Earnings Details
8/15/2013($0.72)($1.47)$2.00 million$2.60 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Portola Pharmaceuticals (NASDAQ:PTLA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 88.43%
Insider Trading History for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals (NASDAQ PTLA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2018Tao FuEVPSell1,135$38.47$43,663.4518,346View SEC Filing  
12/15/2017Henry Ward WolffDirectorSell12,000$47.00$564,000.00View SEC Filing  
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.703,000View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.004,730View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.5018,333View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00706View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.0024,824View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.0029,824View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Portola Pharmaceuticals (NASDAQ PTLA) News Headlines

Source:
DateHeadline
William Blair Comments on Portola Pharmaceuticals Q1 2018 Earnings (PTLA)William Blair Comments on Portola Pharmaceuticals' Q1 2018 Earnings (PTLA)
www.americanbankingnews.com - April 18 at 7:42 AM
FY2020 EPS Estimates for Portola Pharmaceuticals (PTLA) Reduced by William BlairFY2020 EPS Estimates for Portola Pharmaceuticals (PTLA) Reduced by William Blair
www.americanbankingnews.com - April 17 at 7:05 AM
Oppenheimer Increases Portola Pharmaceuticals (PTLA) Price Target to $80.00Oppenheimer Increases Portola Pharmaceuticals (PTLA) Price Target to $80.00
www.americanbankingnews.com - April 16 at 9:48 PM
 Analysts Anticipate Portola Pharmaceuticals (PTLA) Will Post Quarterly Sales of $6.61 Million Analysts Anticipate Portola Pharmaceuticals (PTLA) Will Post Quarterly Sales of $6.61 Million
www.americanbankingnews.com - April 16 at 4:43 AM
Portola Pharmaceuticals (PTLA) Expected to Post Earnings of -$1.46 Per SharePortola Pharmaceuticals (PTLA) Expected to Post Earnings of -$1.46 Per Share
www.americanbankingnews.com - April 14 at 5:17 AM
Portola Pharmaceuticals (PTLA) Given Consensus Rating of "Hold" by BrokeragesPortola Pharmaceuticals (PTLA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 12 at 5:43 PM
Credit Suisse Group Analysts Give Portola Pharmaceuticals (PTLA) a $70.00 Price TargetCredit Suisse Group Analysts Give Portola Pharmaceuticals (PTLA) a $70.00 Price Target
www.americanbankingnews.com - April 10 at 11:39 PM
Portola Pharmaceuticals (PTLA) Upgraded at Zacks Investment ResearchPortola Pharmaceuticals (PTLA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 7:02 AM
Portola Pharmaceuticals (PTLA) Upgraded to Sell by ValuEnginePortola Pharmaceuticals (PTLA) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 3 at 10:07 AM
Today’s Research Reports on Trending Tickers: Intrexon and Portola PharmaceuticalsToday’s Research Reports on Trending Tickers: Intrexon and Portola Pharmaceuticals
finance.yahoo.com - April 3 at 9:16 AM
Portola Pharmaceuticals (PTLA) Receives "Buy" Rating from OppenheimerPortola Pharmaceuticals (PTLA) Receives "Buy" Rating from Oppenheimer
www.americanbankingnews.com - April 1 at 2:38 PM
Portola Pharmaceuticals (PTLA) Stock Rating Reaffirmed by OppenheimerPortola Pharmaceuticals (PTLA) Stock Rating Reaffirmed by Oppenheimer
www.americanbankingnews.com - March 31 at 11:46 AM
Portola Pharmaceuticals (PTLA) Raised to Hold at Zacks Investment ResearchPortola Pharmaceuticals (PTLA) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:16 PM
Investors Buy High Volume of Call Options on Portola Pharmaceuticals (PTLA)Investors Buy High Volume of Call Options on Portola Pharmaceuticals (PTLA)
www.americanbankingnews.com - March 29 at 6:54 AM
Portola Pharmaceuticals Sees Unusually High Options Volume (PTLA)Portola Pharmaceuticals Sees Unusually High Options Volume (PTLA)
www.americanbankingnews.com - March 29 at 6:28 AM
Oppenheimer Analysts Give Portola Pharmaceuticals (PTLA) a $80.00 Price TargetOppenheimer Analysts Give Portola Pharmaceuticals (PTLA) a $80.00 Price Target
www.americanbankingnews.com - March 28 at 3:48 PM
-$1.46 Earnings Per Share Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter-$1.46 Earnings Per Share Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter
www.americanbankingnews.com - March 28 at 9:54 AM
Portola Pharmaceuticals (PTLA) Rating Lowered to Sell at BidaskClubPortola Pharmaceuticals (PTLA) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 25 at 9:50 AM
European advisory group thumbs down on Portolas betrixaban, appeal plannedEuropean advisory group thumbs down on Portola's betrixaban, appeal planned
seekingalpha.com - March 24 at 4:43 PM
Portola Pharmaceuticals (PTLA) PT Set at $67.00 by OppenheimerPortola Pharmaceuticals (PTLA) PT Set at $67.00 by Oppenheimer
www.americanbankingnews.com - March 24 at 2:45 PM
Portola Pharmaceuticals (PTLA) Lowered to "Equal Weight" at Morgan StanleyPortola Pharmaceuticals (PTLA) Lowered to "Equal Weight" at Morgan Stanley
www.americanbankingnews.com - March 24 at 2:12 PM
Portola Pharmaceuticals (PTLA) Downgraded by ValuEngine to Strong SellPortola Pharmaceuticals (PTLA) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 23 at 10:14 PM
Portola Pharma (PTLA) Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for ... - StreetInsider.comPortola Pharma (PTLA) Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for ... - StreetInsider.com
www.streetinsider.com - March 23 at 4:54 PM
EMA panel recommends against Portolas clot prevention drugEMA panel recommends against Portola's clot prevention drug
finance.yahoo.com - March 23 at 4:54 PM
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European UnionPortola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
finance.yahoo.com - March 23 at 4:54 PM
BidaskClub Lowers Portola Pharmaceuticals (PTLA) to SellBidaskClub Lowers Portola Pharmaceuticals (PTLA) to Sell
www.americanbankingnews.com - March 21 at 11:48 PM
Oppenheimer Reiterates Buy Rating for Portola Pharmaceuticals (PTLA)Oppenheimer Reiterates Buy Rating for Portola Pharmaceuticals (PTLA)
www.americanbankingnews.com - March 21 at 1:30 PM
Portola Pharmaceuticals Inc (PTLA) Given Consensus Recommendation of "Hold" by BrokeragesPortola Pharmaceuticals Inc (PTLA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 18 at 5:34 PM
Q1 2018 Earnings Estimate for Portola Pharmaceuticals Inc (PTLA) Issued By OppenheimerQ1 2018 Earnings Estimate for Portola Pharmaceuticals Inc (PTLA) Issued By Oppenheimer
www.americanbankingnews.com - March 16 at 8:10 AM
Portola Pharmaceuticals Inc (PTLA) Forecasted to Post FY2020 Earnings of $2.59 Per SharePortola Pharmaceuticals Inc (PTLA) Forecasted to Post FY2020 Earnings of $2.59 Per Share
www.americanbankingnews.com - March 15 at 2:24 PM
Portola Pharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($1.42) Per Share (PTLA)Portola Pharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($1.42) Per Share (PTLA)
www.americanbankingnews.com - March 15 at 6:45 AM
Tao Fu Sells 1,135 Shares of Portola Pharmaceuticals Inc (PTLA) StockTao Fu Sells 1,135 Shares of Portola Pharmaceuticals Inc (PTLA) Stock
www.americanbankingnews.com - March 14 at 10:41 PM
Portola Pharmaceuticals Inc (PTLA) to Post Q4 2019 Earnings of $0.28 Per Share, William Blair ForecastsPortola Pharmaceuticals Inc (PTLA) to Post Q4 2019 Earnings of $0.28 Per Share, William Blair Forecasts
www.americanbankingnews.com - March 14 at 3:27 PM
Portola Pharmaceutical's AndexXa Approval Remains UncertainPortola Pharmaceutical's AndexXa Approval Remains Uncertain
finance.yahoo.com - March 14 at 9:50 AM
Portola Pharmaceuticals (PTLA) Earns Buy Rating from William BlairPortola Pharmaceuticals (PTLA) Earns Buy Rating from William Blair
www.americanbankingnews.com - March 13 at 3:52 PM
Portola Pharmaceuticals (PTLA) Given "Buy" Rating at Credit Suisse GroupPortola Pharmaceuticals (PTLA) Given "Buy" Rating at Credit Suisse Group
www.americanbankingnews.com - March 13 at 3:10 PM
Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening BleedingPortola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa® (Andexanet Alfa) in Patients with Life-Threatening Bleeding
finance.yahoo.com - March 12 at 5:53 PM
Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General ... - NasdaqPortola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General ... - Nasdaq
www.nasdaq.com - March 12 at 11:45 AM
Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General CounselPortola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel
finance.yahoo.com - March 12 at 11:45 AM
Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a SlumpWhy Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump
finance.yahoo.com - March 12 at 11:45 AM
Zacks: Analysts Expect Portola Pharmaceuticals Inc (PTLA) Will Announce Quarterly Sales of $6.38 MillionZacks: Analysts Expect Portola Pharmaceuticals Inc (PTLA) Will Announce Quarterly Sales of $6.38 Million
www.americanbankingnews.com - March 12 at 2:16 AM
Portola Pharmaceuticals (PTLA) Upgraded at BidaskClubPortola Pharmaceuticals (PTLA) Upgraded at BidaskClub
www.americanbankingnews.com - March 11 at 3:52 PM
 Brokerages Expect Portola Pharmaceuticals Inc (PTLA) to Post -$1.54 Earnings Per Share Brokerages Expect Portola Pharmaceuticals Inc (PTLA) to Post -$1.54 Earnings Per Share
www.americanbankingnews.com - March 10 at 11:10 PM
Portola Pharmaceuticals: What The Latest Developments Regarding AndexXA Entail? - Seeking AlphaPortola Pharmaceuticals: What The Latest Developments Regarding AndexXA Entail? - Seeking Alpha
seekingalpha.com - March 7 at 5:41 PM
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola PharmaceuticalsToday’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Portola Pharmaceuticals
finance.yahoo.com - March 7 at 9:11 AM
Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesPortola Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - March 6 at 5:06 PM
Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet AlfaPortola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa
finance.yahoo.com - March 5 at 5:20 PM
Portola Pharmaceuticals Inc (PTLA) Shares Bought by Sectoral Asset Management IncPortola Pharmaceuticals Inc (PTLA) Shares Bought by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 3:33 PM
Portola Pharmaceuticals Inc (PTLA) Holdings Boosted by Wells Fargo & Company MNPortola Pharmaceuticals Inc (PTLA) Holdings Boosted by Wells Fargo & Company MN
www.americanbankingnews.com - March 5 at 3:10 PM
Portola Pharmaceuticals Inc (PTLA) Shares Bought by UBS Asset Management Americas Inc.Portola Pharmaceuticals Inc (PTLA) Shares Bought by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 5 at 9:42 AM

SEC Filings

Portola Pharmaceuticals (NASDAQ:PTLA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Portola Pharmaceuticals (NASDAQ:PTLA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Portola Pharmaceuticals (NASDAQ PTLA) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.